Last reviewed · How we verify
Lispro Low Mix
Lispro Low Mix is a fixed-ratio combination of rapid-acting insulin lispro and intermediate-acting insulin lispro protamine suspension that mimics physiologic insulin secretion by providing both mealtime and basal insulin coverage.
Lispro Low Mix is a fixed-ratio combination of rapid-acting insulin lispro and intermediate-acting insulin lispro protamine suspension that mimics physiologic insulin secretion by providing both mealtime and basal insulin coverage. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Lispro Low Mix |
|---|---|
| Also known as | Humalog Mix 75/25 |
| Sponsor | Eli Lilly and Company |
| Drug class | Insulin combination product |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
The rapid-acting component (insulin lispro) is absorbed quickly to cover postprandial glucose excursions after meals, while the intermediate-acting component (insulin lispro protamine) provides longer-duration basal insulin coverage between meals and overnight. This combination allows for twice-daily dosing that approximates the body's natural biphasic insulin response to food intake and fasting periods.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- Comparison of Insulin Mix25 Versus Mix50 (PHASE4)
- Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies (PHASE4)
- Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast (PHASE4)
- The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV) (PHASE4)
- Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 Diabetes (PHASE4)
- 24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine (PHASE4)
- Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019) (PHASE4)
- A Study for Patients With Diabetes Mellitus (IOPA) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |